Ryan Specialty Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYAN research report →
Range $40 – $69
Price Chart
About the company
Ryan Specialty Holdings, Inc. functions as a provider of specialized insurance products and comprehensive solutions for the benefit of insurance brokers, agents, and carriers. The company delivers a range of services including distribution, underwriting, product development, administration, and risk management, primarily through its roles as a wholesale broker and a managing underwriter.
- CEO
- Timothy William Turner
- IPO
- 2021
- Employees
- 6,129
- HQ
- Chicago, IL, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend, trading well above its 200-day average of 38.84 and 50-day average of 41.61. It remains below the 52-week high of 58.13, so the setup is stronger than the long-term base but not yet fully extended.
Street sentiment stays constructive, with a Buy consensus and a 48.5 target that sits above the current share price. Recent action has been mixed but mostly steady, with several firms trimming targets into the low-40s while others still sit at 50 to 55, signaling cautious optimism rather than a full re-rating.
Execution has been solid, with 3 straight EPS beats and 4 beats in the last 8 quarters. Next-year EPS estimates point higher to 2.43 from 2.18 for 2026, so shareholders should watch whether specialty brokerage growth and margin discipline can keep the beat streak alive.
The pattern leans negative on discretionary activity, led by CEO Benjamin Wuller’s recent open-market sales after a series of exempt transactions and a gift. The co-president also sold shares after conversion-related activity, while the director entries look like ownership changes rather than fresh buying. No meaningful insider accumulation stands out.
Profitability is healthy, with a 19.8% operating margin, 41.1% gross margin, and 25.2% ROE. Growth is still positive but moderate, with revenue up 4.8% year over year and earnings up 43.1%, while free cash flow of $711.6 million and $5.95 per share support the model.
RYAN’s specialty-broker model supports above-average margins and steadier earnings than many financial peers. The stock trades at 22.74x earnings, a premium that reflects quality, but it leaves less room for disappointment versus the broader insurance-broker group.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.64B
- P/E
- 46.09
- Fwd P/E
- 21.59
- PEG
- 0.55
- P/S
- 1.72
- P/B
- 12.67
- EV/EBITDA
- 11.31
- Div Yield
- 1.12%
- Gross Margin
- 91.39%
- Op Margin
- 19.53%
- Net Margin
- 5.95%
- ROE
- 34.57%
- ROIC
- 9.98%
Latest fiscal year · YoY change
- Revenue
- $3.05B+21.3%
- Gross Profit
- $2.76B+9.9%
- Op Income
- $625.23M
- Net Income
- $63.40M-33.0%
- EPS
- $0.50-35.9%
- OCF Growth
- +25.0%
- FCF Growth
- +23.1%
- 52W High
- $58.91
- 52W Low
- $29.28
- 50D MA
- $41.76
- 200D MA
- $38.83
- Beta
- 0.60
- RSI (14)
- 57
- Avg Volume
- 1.98M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ryan Specialty posted solid third-quarter growth with revenue up 4.7% and EPS up 8.5%, while margin pressure from hiring and a tougher pricing environment was offset by disciplined cost control and continued share repurchases.· October 29, 2026
- Total revenue rose 4.7% to $790 million; adjusted EBITDAC increased 3.8% to $244 million and adjusted EPS grew 8.5% to $0.51.
- Organic revenue growth was 4% in the quarter, bringing 9M 2026 organic growth to 7.3%.
- Adjusted EBITDAC margin was 30.9% versus 31.2% a year ago; management said 2026 margin guidance improved to down modestly year over year, from down 50 to 100 bps previously.
- The company repurchased 3.5 million shares for $150 million in the quarter and had $100 million remaining under authorization as of today.
- Management sees continued property price declines, broader casualty competition, and softer binding authority conditions, but also highlighted strong talent, new product launches, and AI-related opportunities.
In Q3 2026, total revenue was $790 million, up 4.7% year over year, driven by 4% organic revenue growth plus contributions from M&A and contingent commissions. Adjusted EBITDAC was $244 million, up 3.8%, with adjusted EBITDAC margin at 30.9% versus 31.2% in the prior-year period. Adjusted EPS was $0.51, up 8.5%. For the first nine months of 2026, organic revenue grew 7.3%, adjusted EBITDAC grew 7.9%, and adjusted EPS grew 15.1%. For 2026, management continues to guide to organic revenue growth toward the higher end of its mid-single-digit range and now expects full-year adjusted EBITDAC margin to be down modestly year over year (previously down 50 to 100 basis points). The company also expects a similar adjusted tax rate of about 26% in Q4 and about $59 million of GAAP interest expense net of interest income in Q4. Capital allocation remained active, with 3.5 million shares repurchased for $150 million in the quarter and 1.3 million shares for $50 million in October; $100 million remained under authorization, and net leverage ended at 3.3x.
Patrick Ryan emphasized the resilience of the platform in a very challenging market, saying the team delivered through intense competition, continued investment, and disciplined expense management. He highlighted specialty expertise, independence, and the structural growth of E&S and delegated authority as core advantages, and said AI is a tool that enhances specialists rather than replacing them. His tone was confident and strategic, with a strong emphasis on talent, innovation, and long-term positioning.
Janice Hamilton focused on the financial discipline behind the quarter’s results. She said the margin outlook improved because of cost discipline, the expected lap of the late-2025 talent investment next year, and progress from Empower, partially offset by higher healthcare and benefits costs and flat fiduciary investment income. She also noted the company ended the quarter at 3.3x total net leverage, within its 3 to 4x comfort corridor, and reiterated capital priorities of M&A and share repurchases alongside a modest and sustainable dividend.
Analysts focused on whether business is flowing back to the admitted market, what 2027 could look like, and how much new capacity and talent could help growth. Management said it does not see a measurable amount of business moving back to admitted; rather, the main issue is fierce competition inside non-admitted markets, especially in property and some casualty and binding authority segments. They also said 2027 is not being guided yet, but pointed to continued secular tailwinds, a strong pipeline in reinsurance and AI/data-center-related opportunities, and the expectation that the 2025 hiring class becomes more fully accretive over time. On M&A, Pat Ryan said 2027 looks like a more robust year than the last couple of years and could bring more opportunities.
The call reinforced that Ryan Specialty is still growing organically above a tough market backdrop, with 4% organic growth in the quarter and 7.3% year to date. Management believes structural tailwinds in E&S, delegated authority, specialty expertise, AI-related risks, and new product launches should keep creating opportunities, while the 2025 hiring class and ongoing AI tools may support future growth and efficiency.
Management repeatedly flagged a difficult pricing environment, especially continued property price declines, broader casualty competition, and intensified competition in binding authority. They also pointed to softness in builders’ risk, more moderate transactional liability growth, and margin pressure from hiring investments and higher healthcare costs. 2027 was discussed as promising, but no formal guidance was given, and management acknowledged that some lines remain lumpy and highly competitive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.3%
- Shares Outstanding
- 119.69M
- Float Shares
- 104.55M
of shares held by institutions
379 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 10.23M | ▼ 46.89K |
| Blackrock, Inc. | 10.18M | ▼ 313.69K |
| Vulcan Value Partners, LLC | 6.87M | ▼ 1.05M |
| T. Rowe Price Investment Management, Inc. | 6.37M | ▼ 254.20K |
| Neuberger Berman Group LLC | 6.24M | ▲ 671.93K |
| Orbis Allan Gray Ltd | 5.44M | ▼ 864.96K |
| Vanguard Capital Management LLC | 4.72M | ▼ 495.12K |
| Vanguard Portfolio Management LLC | 4.66M | ▼ 605.52K |
| Valueact Holdings, L.P. | 3.68M | ▲ 3.68M |
| State Street Corp | 3.66M | ▼ 47.79K |
| Fmr LLC | 3.39M | ▼ 1.74M |
| Polar Capital Holdings PLC | 2.94M | 0 |
Held by 450 ETFs
Biggest fund positions in RYAN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Wuller Benjamin MIles | other | 40,000 |
| Nov 9, 26 | Wuller Benjamin MIles | other | 40,000 |
| Nov 10, 26 | Wuller Benjamin MIles | other | 50,000 |
| Nov 10, 26 | Wuller Benjamin MIles | other | 50,000 |
| Nov 10, 26 | Wuller Benjamin MIles | other | 50,000 |
| Nov 10, 26 | Wuller Benjamin MIles | sell | 50,000 |
| Nov 9, 26 | Wuller Benjamin MIles | sell | 50,000 |
| Nov 10, 26 | Wuller Benjamin MIles | other | 7,577 |
| Oct 29, 24 | Wuller Benjamin MIles | other | 0 |
| Sep 4, 26 | MULSHINE BRENDAN MARTIN | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RYAN coverage
Recent articles, reports, and earnings notes.

Ryan Specialty Group (RYAN): Growth Mix Shift, But Leverage Matters
Ryan Specialty is growing through a favorable mix shift toward underwriting management, but investors need to watch leverage and margin pressure. The report supports a Buy with a fair value of $43.00.

Ryan Specialty (RYAN): Specialty Insurance Growth vs. Leverage
Ryan Specialty posted solid revenue and EPS growth, but near-term upside is capped by softer property pricing, rising competition, and a leveraged balance sheet. The stock looks like a steady specialty-insurance compounder, but not an obvious bargain at current levels.

Ryan Specialty Holdings, Inc. (RYAN) climbs 14% after hours
Ryan Specialty Holdings, Inc. (RYAN) climbs sharply after hours as investors position for its upcoming Q2 2026 earnings release. The move follows strong prior-quarter growth, but the stock’s premium valuation and elevated debt mean traders should wait for confirmed regular-session strength.
Want a deeper read on RYAN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Ryan Specialty Q3 Earnings Call Highlights
marketbeat.com · Oct 30
Ryan Specialty Holdings, Inc. (RYAN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Ryan Specialty Group (RYAN) Q3 Earnings and Revenues Beat Estimates
zacks.com · Oct 29
Ryan Specialty (RYAN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Oct 29
Ryan Specialty Reports Third Quarter 2026 Results
businesswire.com · Oct 29
What to Expect From These 3 Insurance Brokers This Earnings Season?
zacks.com · Oct 28
Can Ryan Specialty (RYAN) Keep the Earnings Surprise Streak Alive?
zacks.com · Oct 27
Ryan Specialty Group (RYAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice